The data add to growing evidence supporting the use of HER2 therapy across solid tumors, though researchers find a difficult path to a tissue-agnostic approval.
The firm saw modest growth across both of its business segments and double-digit growth in its droplet digital PCR product line.
Two new grants are helping the company develop its SHERLOCK and INSPECTR technologies as the basis for creating innovative diagnostics.
The Unity test enables screening for several autosomal recessive conditions from fetal DNA gathered from maternal blood.
The firm's tool combines enzymatic and mechanical disruption to produce viable and accurate products for downstream single-cell applications.
By combining conventional karyotyping and low-pass sequencing, researchers found chromosomal abnormalities in 1 in 8 couples with recurrent miscarriage.
Researchers documented population structure, ancestry patterns, trait associations, and more with variants found in the genomes of more than 6,400 Ugandans.
Nature Papers Examine Residual Protein Expression Following CRISPR Knockout, Polygenic Score Predicts Depression Risk
In Nature this week: residual protein expression uncovered for a third of CRISPR targets, and more.
NanoString Technologies has appointed Don Kania to its board of directors, effective Oct. 30, 2019. Kania has more than 25 years of experience in scientific research and development, global operations, and manufacturing. Most recently, he served as CEO, president, and member of the board of directors of FEI Company until its 2016 acquisition by Thermo Fisher Scientific. He also held various positions at Veeco Instruments, ultimately as chief operating officer. Prior to that he held technical and general management positions at Lawrence Livermore National Laboratory and Los Alamos National Laboratory.
Kania currently serves on the board of directors of robotic-assisted surgery firm Intuitive Surgical. He is also on the board of trustees of the Oregon Health & Science University Foundation and serves as an advisor to several privately held life sciences companies. He holds BS, MS, and PhD degrees in physics and engineering from the University of Michigan.
SeraCare Life Sciences has released what it says are the first available genomic DNA and formalin-fixed paraffin-embedded reference materials for tumor mutational burden measurement by next-generation sequencing assays. The company created the new materials as part of its work with the Friends of Cancer Research TMB harmonization working group and the International Quality Network for Pathology's TMB EQA Pilot Program.
Data generated from using the reference samples was presented by FOCR at the 2019 American Society of Clinical Oncology Meeting, and by IQN Path at the 2019 European Congress of Pathology, demonstrating their utility in harmonizing and standardizing measurements of TMB by different NGS assays.
In addition to the new SeraSeq TMB gDNA and FFPE materials available now, SeraCare said it can also create custom tissue and blood-based TMB reference materials through its VariantFlex custom reference material development platform.
A CFTR gene mutation found in 90 percent of US cystic fibrosis patients was only present in a third of Puerto Rican and 10 percent of Dominican patients.
With genome sequencing, investigators tracked down a sole stool donor carrying the same multi-drug resistant form of Escherichia coli found in two FMT recipients with bacteremia.
The number of technologies to be assessed is vast, and ranges from liquid biopsies and molecular imaging to immunohistochemistry and RNA-seq.
Becton Dickinson has released a new solution for combined whole-transcriptome and protein analysis in single cells.
The BD Rhapsody Whole Transcriptome Analysis Amplification Kit enables unbiased 3'-based capture, amplification, and detection and is designed to work with BD's Rhapsody single-cell analysis system and AbSeq reagents. It is also optimized to work with BD's Single-Cell Multiplexing kit to improve efficiency.
The research-use-only kit is validated for use with a wide range of cell inputs.
Thermo Fisher Scientific has launched the Oncomine Comprehensive Assay Plus for the detection of targeted and immuno-oncology biomarkers. The assay, designed for solid tumors, covers more than 500 genes and enables analysis of both DNA and RNA in a single workflow. It detects single nucleotide variants, indels, copy number variants, gene fusions, and splice variants and is suitable for microsatellite instability (MSI) and tumor mutational burden (TMB) assessment. The assay requires 1 ng DNA/RNA input and fits seamlessly into existing Thermo Fisher Ion Chef and Ion GeneStudio system workflows.
Single-cell biology company Namocell has appointed Bob Cao as VP of engineering. Cao spent 12 years at Becton Dickinson's BD Biosciences, where he led engineering efforts for multiple flow cytometry platforms. He also previously held product development lead roles at 10x Genomics and Complete Genomics.
Yourgene of Manchester, UK, has launched the Yourgene Flex Analysis Software to support the company's plans to develop next-generation sequencing-based in vitro diagnostic products with partners and research collaborators in industry. The software platform builds on the company's Iona software and will also be deployed internally to support Yourgene's internal product development pipeline in reproductive health and oncology. Its components allow for sequence data to be read, filtered, and analyzed, and to generate bespoke clinical test reports. All elements of the software are developed to standard ISO/IEC 62304, which supports in vitro diagnostic regulatory submissions.
The company also said that it has acquired Beijing-based food safety testing firm Meizheng Group. The deal is expected to expand PerkinElmer's food safety capabilities.
The company reported increase US and international revenues and test volumes, driven by increased adoption and expanding public and private payor coverage.